Close Menu

NEW YORK – Biotia, a startup providing DNA sequencing-based microbial surveillance services and infectious disease diagnostic tests for hospitals, said Tuesday that it has closed a $2.4 million seed financing round.

Falcon III Ventures, a Boston-based biotech fund, led the round, with participation from other venture capital firms and angel investors, according to Biotia. 

The company also added Barry Zeman, Don Goldmann, and Steven Salzberg to its scientific and clinical advisory board. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.